HECTOROL
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $6,644 | 2 | 0 |
| 2023 | $29,129 | 9 | 1 |
| 2022 | $73,405 | 20 | 1 |
| 2021 | $196,127 | 36 | 0 |
| 2020 | $86,787 | 44 | 0 |
| 2019 | $347,684 | 97 | 0 |
| 2018 | $157,568 | 246 | 0 |
| 2017 | $35,660 | 64 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $927,898 | 514 | 99.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,093 | 3 | 0.5% |
| Food and Beverage | $12.12 | 1 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) in Pediatric Patients With Chronic Kidney Disease Stages 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis | GENZYME CORPORATION | $385,551 | 0 |
| An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) in Pediatric Patients With Chronic Kidney Disease Stages 3 and 4 With Secondary | GENZYME CORPORATION | $319,918 | 0 |
| An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) in Pediatric Patients With Chronic Kidney Disease Stages 3 and 4 With Secondary | SANOFI US SERVICES INC. | $193,216 | 0 |
| An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol? (Doxercalciferol Capsules) in Pediatric Patients With Chronic Kidney Disease Stages 3 and 4 With Seconda | SANOFI US SERVICES INC. | $27,766 | 0 |
| An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) in Pediatric Patients With Chronic Kidney Disease Stages 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis | SANOFI US SERVICES INC. | $1,448 | 0 |
Manufacturing Companies
- GENZYME CORPORATION $705,469
- SANOFI US SERVICES INC. $222,430
- SANOFI-AVENTIS U.S. LLC $5,105
Product Information
- Type Drug
- Total Payments $933,003
- Total Doctors 2
- Transactions 518
About HECTOROL
HECTOROL is a drug associated with $933,003 in payments to 2 healthcare providers, recorded across 518 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2017 to 2024. In 2024, $6,644 was paid across 2 transactions to 0 doctors.
The most common payment nature for HECTOROL is "Unspecified" ($927,898, 99.5% of total).
HECTOROL is associated with 5 research studies, including "An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) in Pediatric Patients With Chronic Kidney Disease Stages 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis" ($385,551).